Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, M.D., M.P.H., Head of Development at Biogen.

“At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “With his diverse background in medicine, public health, and business administration, and his extensive experience in medical affairs across both US and global markets, Dan is well-positioned to help drive our leadership forward as we expand further into neurology, immunology, and rare diseases.”

Prior to joining the Biogen team, Dr. Quirk was Senior Vice President of Worldwide Medical Affairs for Immunology and Neuroscience at Bristol-Myers Squibb (BMS), and previously served as Senior Vice President of US Medical Affairs and Vice President of US Medical Affairs for Immunology and Fibrosis at BMS. Earlier in his career, Dr. Quirk held several key leadership positions at Pfizer, with the most recent being Vice President and Medical Category Lead for Inflammation and Immunology in Emerging Markets.

Dan enjoyed a successful medical career before joining industry and served as the Associate Chief of Gastroenterology at Thomas Jefferson University Health Systems in Philadelphia, where he contributed significantly to patient care, clinical research, and medical education.

Dr. Quirk earned his M.D. from Brown University, followed by an M.P.H. from the Harvard School of Public Health and an M.B.A. from The Wharton School at the University of Pennsylvania. Dr. Quirk completed his medical training at the Johns Hopkins Hospital and the Massachusetts General Hospital.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor
This news release contains forward-looking statements, including regarding the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of investments, and Biogen’s future strategic and financial results. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; actual timing and content of submissions to and decisions made by the regulatory authorities regarding our products or product candidates; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.

MEDIA CONTACT:
Biogen
Jack Cox
+ 1 781 464 3260
public.affairs@biogen.com

INVESTOR CONTACT:
Biogen
Stephen Amato
+1 781 464 2442
IR@biogen.com